According to European Biotechnology Magazine, “with more than 600 senior executives from the Swiss life science industry and from across Europe the annually held was as popular as never before in its 11-year history. (Click here for a selection of pictures from the event.) The programme in the afternoon included a session on fostering closer co-operations between Swiss and UK life sciences companies and investors. Moreover, a discussion about financing biotech projects and companies in an extraordinary scattered-around-the-hall setting was well-received, as were the three hours packed with presentations of more than a dozen young companies and start-ups.
The biotechnology sector in Switzerland is growing more strongly than it has done for years. According to the new Swiss Biotech Report published at the event, in 2017 the 237 biotech companies and 60 suppliers of the industry employed more than 13,700 staff (+2.5%) and posted a turnover of CHF3,79bn (+14%). Compared to the previous year, capital investment in private and listed Swiss biotech companies doubled from CHF0.8bn to CHF1.64 billion – the highest figure since the report was first published. In addition, investment in research and development increased by more than 22% to CHF1.39bn. The value of pharmaceutical and biotechnology product exports in 2017 was CHF83.8bn, which is about 38% of the total Swiss export volume.”
At AA Thornton we have a great deal of experience dealing with a wide number of innovations in Pharmaceuticals and Biotechnology. If you would like further information, or would like to discuss industry developments, then please do not hesitate to contact one of our Pharmaceuticals attorneys.